




Your Concerns, Our Solution

The Magellan™ Safety Needle



Healthcare Workers should feel safe and comfortable as they perform their valuable roles: In a recent Europe-wide survey **82% reported major concern over the threat of needlestick injuries**, with the infection of HIV and Hepatitis foremost in their fears.¹



The Covidien Safety Day reported these findings across **Europe**:

The problem of needlestick injuries

- *Across Europe, 83% of healthcare workers responded that they were concerned about needlestick injuries compared to other workplace injury risks.¹*
- *59% of healthcare workers asked in our survey reported having experienced a needlestick injury themselves.¹*
- *94% of respondents know a colleague who has experienced a needlestick injury.¹*
- *The main concern for 82% of those questioned in regards needlestick injury was the infection of blood borne diseases, with 20% specifying the threat of HIV and 15% referencing Hepatitis.¹*

Focus on Europe

The protection they deserve

This document explores some of the issues surrounding needlestick injuries. It provides guidance and information concerning recent legal changes to protect Healthcare workers, and examines a recent survey conducted by Covidien that highlights the health risks and costs involved with this serious problem.



The Solution


The Magellan™ Safety Needle

- 94% feel the safety feature on the Magellan™ Safety Needle is **effective in reducing needlestick injuries.**¹
- 92% agreed that the safety feature is **easily activated.**¹
- 93% agree that the safety feature causes **no splashing** during activation.¹
- 96% feel the product has a **good ability** to pierce the skin in regular use.¹
- 89% of those asked Europe-wide would use this product.¹



CONTENTS

Guidance	Need for Safety	Innovative Design	User Preferences	Implications	Magellan™ delivering safety
EU Directive	Profiles	Simplicity	Optionality	Training	Conclusion
Toolkits	Concerns	Handling	Visibility	Costs	
Studies	Risks	Ergonomics	Penetration	Absenteeism	
	Incidence	Restraints	Effectiveness	Legal	
	Injuries	Activation	Splashing		
	Frequency	Would I use?	Time		
			Safety		



3 questions to ask...

1. Are you the person responsible for procuring safety needles and syringes?

2. What type or brand of product is normally chosen and what is your rate of use?

3. What decisions have you taken to comply with the EU directive?

5 reasons why you should choose Magellan™ safety needles

1. Proven Safety

Once the Magellan™ safety shield is activated, it cannot be deactivated, and the shield remains in effect even after disposal.

2. Easier to Use

Magellan's small profile makes it less bulky than other safety shields, eliminating obstructions of the injection site and the syringe graduations.

3. Easy and Safe to Activate

Three ways of activating the safety device – using a finger, thumb or flat surface. The clinician's hand remains behind the needle at all times, eliminating user risk. Audible click when activated.

4. Market Leading Brand

The Magellan™ is one of the most popular safety needle devices used in the United States today. Its proven reliability and functionality is now available in Europe, delivering the quality standard expected from Covidien.

5. Trusted by Users

With 12 years experience in the market, the Magellan™ is a product with a solid track record and reputation. The Magellan™ range has been developed and improved to meet healthcare workers' needs and demands.

What is the EU directive 2010/32/EU?

Directive 2010/32/EU requires that formal risk assessments are performed on all activities where medical sharps are used, and that wherever there is a risk of injury or infection it must be minimized by means of training, improved working practices – and the introduction of safety-engineered medical devices, such as the Magellan™ safety needle.

Who does the Directive protect?

The EU Directive covers all workers that are under the managerial authority and supervision of healthcare employer/organisations, including those providing healthcare in the home, in nursing and care homes, doctors' offices, dental surgeries and other non-hospital settings, and any private or independent healthcare employers. Additionally the directive covers some self-employed workers (such as agency/bank nurses), and any sub-contracted staff providing services for healthcare organisations (e.g. cleaners). Furthermore, it also incorporates any students whilst they are under the supervision of a healthcare provider.

Why and when is the new EU Directive being introduced?

Existing legislation was largely ignored or misinterpreted, and as a result proved ineffective. The Directive implementation date is 13 May 2013.

EU Directive

“Eliminating the unnecessary use of sharps by implementing changes in practice and providing medical devices incorporating safety-engineered protection mechanisms.”

Further information

Further information on the EU directive can be found in these information toolkits (All are available for download):

- EPN Toolkit for implementation of the European Directive
- Royal College of Nursing guidance to support implementation of the EU Directive 2010/32/EU on the prevention of sharps injuries in the Healthcare sector
- Prevention of Sharps Injuries in the Hospital and Healthcare Sector Implementation
- Guidance for the EU Framework agreement


Need for Safety - Key Findings¹

PROFILES

QUESTION

What is your Job title?


RESULTS



QUESTION

What type of ward or department are you based in?

RESULTS




CONCERNS

QUESTION

What is your main concern in regards a future needlestick injury?

RESULTS



With over 8 out of 10 respondents expressing concern over the potential transmission of infection and disease through a needlestick injury it is clear a solution must be found to offer Healthcare workers the protection and peace of mind they deserve.




RISKS

QUESTION

Compared to other workplace related injuries, how concerned are you about the risk of a needlestick injury?

KEY FINDING




83%
were most concerned about needlestick injuries.¹

INCIDENCE

QUESTION

Currently needlestick injuries are reported by 1 in 10 healthcare professionals, do you think this accurately reflects the reality?

KEY FINDING




62%
of those questioned believe needlestick incidents are under-reported.¹

INJURIES

QUESTION

Have you ever experienced a needlestick injury?

KEY FINDING




59%
of those questioned had experienced a needlestick injury themselves.¹

FREQUENCY

QUESTION

Do you know any colleagues who have had a needlestick injury?

KEY FINDING



94%
of people surveyed said they knew a colleague who had suffered a needlestick injury.¹

With an estimated 1 million needlestick injuries occurring annually in Europe², the Magellan™ safety needle can help reduce incidence and deliver peace of mind.

100% of respondents agreed it is a better alternative to traditional recapping.¹

Innovative Design - Key Findings¹



SIMPLICITY

QUESTION

Is the Magellan™ safety needle's safety feature easily activated?

BENEFITS

Intuitive one-handed operation minimises training costs and disruption.

The safety shield is designed as an integral part of the device.

Needles are available on their own or pre-attached to syringe saving valuable nursing time and maximising efficiency.


DIRECTIVE

'The product must be easy to use and require little change of technique on the part of the health professional'

EBN Toolkit

OPINION

With 9 out of 10 respondents agreeing the safety feature is easily activated without special training¹ it is apparent the Magellan™ safety needle finds favour with Healthcare Workers through its intuitive ease-of-use, and can be implemented without disruptive and costly training.



WHY? Intuitive, easy one-handed safety activation.

HANDLING

QUESTION

Is the safety feature easy to use and handle?

KEY FINDING




ERGONOMICS

QUESTION

Can the safety feature be activated with one hand?

KEY FINDING



DIRECTIVE

'The safety mechanism must be an integral part of the safety device, not a separate accessory.'

'The device must not create other safety hazards or sources of blood exposure.'


EPN Prevention of Sharps Injuries in the Hospital and Healthcare Sector.

RESTRAINTS

QUESTION

Does the safety feature hinder routine use?

KEY FINDING




87%
of respondents agreed that the safety feature does not hinder routine use.¹

ACTIVATION

QUESTION

Is the safety feature activation clearly communicated to the user?

KEY FINDING



94%
felt the safety feature activation was clearly communicated to the user.¹

Magellan™ has an audible click when activated.

DIRECTIVE

'The device must perform reliably.'

'The activation of the safety mechanism must manifest itself by means of an audible, tactile or visual sign to the health professional.'


EPN Prevention of Sharps Injuries in the Hospital and Healthcare Sector.

WOULD I USE?

QUESTION

Would I use this product?

KEY FINDING



90%
of respondents said that they would use this product, implying strong trust in its design to protect from needlepoint injuries, and appreciation of its user features.¹


BENEFITS

Bevel orientation saves valuable nursing time; when the safety device is up it does not interfere with the view when delivering.

Needle-based safety technology promotes clinical flexibility.

Safety needle may be connected to any standard luer lock syringe.

Latex free: Eliminates potential reaction.




User Preferences - Key Findings¹

OPTIONALITY

QUESTION

Is there a good range of sizes available?

KEY FINDING



89%
said there is a good range of sizes available.¹

BENEFITS

Available as needle only or pre-attached combinations.


Available with needles pre-attached to the syringe saves valuable nursing time and improves efficiency.

VISIBILITY

QUESTION

Does the safety feature hinder visualisation at the tip of the needle?

KEY FINDING



89%
agreed the safety feature does not hinder visualisation of the needle.¹

WHAT SIZES ARE AVAILABLE?

Gauge Sizes range from 18 to 25 gauge and needle lengths are available in 5/8", 1" and 1-1/2".



OPINION

Over 9 out of 10 Healthcare Workers across Europe were happy that there was a good range of sizes available¹: The Magellan™ safety needle provides good optionality to cover your specific requirements.

“Simplifies the standardization efforts from standard needle and syringe products to safety.”

SAFETY

Almost 9 out of 10 respondents felt the safety feature did not hinder routine use¹, meaning the effective benefits of the Magellan™ safety needle are appreciable without sacrificing everyday performance. With 94% reporting no splashing once the safety feature is activated, and an ultra sharp, tri-beveled, anti-coring needle this product has a number of advantages.



REMEMBER EU Directive: 2010/32/EU –
the implementation date is 13 May 2013


DIRECTIVE
'Avoid the risks where possible.'
EBN Toolkit

EFFECTIVENESS

QUESTION

The safety feature would be effective in reducing needlestick injuries?

KEY FINDING



94%
of respondents felt the *Magellan™ safety needle* would be effective in reducing needlestick injuries.¹

BENEFITS


Audible and tactile click confirms safety device has been activated.

SPLASHING

QUESTION

Does the safety feature cause splashing when activated?

KEY FINDING




94%
told us there is no splashing when the safety feature is activated.¹

PENETRATION

QUESTION

Does the product have a good ability to penetrate the skin?

KEY FINDING



95%
said the product penetrated the skin well.¹


BENEFITS

Minimises trauma to muscle tissue for smooth delivery of medications.

TIME

The safety feature does not require more time to use than conventional methods.

KEY FINDING



88%
agreed the safety feature is as fast as conventional methods.¹


Implications - Key Findings¹

TRAINING

QUESTION

Does the product require detailed training?

KEY FINDING



92%
said the product does not require detailed training.¹

One-handed safety activation.

- Minimises training and in-service needs
- Convenient and easy to implement
- Satisfies EU Directive best practice preference

Key design features:

- Integral safety device
- Finger always behind the needle
- Can't be reactivated
- Audible click

DIRECTIVE

'The device must be easy to use and require little change of technique on the part of the health professional.'

EBN Toolkit

'A single-handed or automatic activation is preferable.'

EPN Prevention of Sharps Injuries in the Hospital and Healthcare Sector

COSTS

EPINet[®] reports that the four categories for follow-up charges after needlestick injuries are as follows:

- Laboratory charges for blood tests.
- Charges for treatments e.g. hepatitis B, drugs for HIV, and tetanus vaccine.
- Money for emergency department or employee health department visits or other services.
- Other costs such as surgery, personal costs, loss of salary, as well as legal bills from litigating circumstances.³

In Spain, the annual cost of needlestick injuries is €6-7(million) and the annual cost of injection/IV-related needlestick injuries is €4-5 (million).⁴

In Austria the cost per person to cover needlestick injuries is €162.50 for the blood analysis, and €500 for the medical therapy (per year).

In Germany the average cost for a needlestick injury is €450.⁵ In Italy, it's €850.⁶ In Poland, the cost of drugs for doctor or nurse against hepatitis B is €470 - €700.

The cost of drugs for a doctor or a nurse to protect themselves against HIV is about €2,654 and the cost of complications in the event of infection is €17,777.

In the UK, the Bevan Brittan report estimated that needle stick injuries cost each trust £500,000 each year⁷ with the cost of an injury ranging from €403.59 for patients with low risk to €1761.97 for patients with unknown risk.⁸




Fig 1. The cost of a needlestick injury per person in each country

**REMEMBER EU Directive: 2010/32/EU –
the implementation date is 13 May 2013**

ABSENTEEISM

There is the additional service and economic cost of absenteeism. For example a hospital in the UK with 5,000 staff can spend around £100,000 annually on managing exposure incidents, including the costs of blood tests, lost staff time and post-exposure prophylaxis (excluding litigation costs). A recent large survey commissioned by the Scottish Executive demonstrated that in the case of sharps injuries 41% could probably be prevented, whilst 14% could definitely be prevented by the use of safety devices. Applying these figures to a hospital with 5,000 staff gives estimated annual savings of £14,000 - £42,000.⁹

There are significant economic, health, emotional and social issues arising from needlestick injuries. The Magellan™ safety needle can minimize incidence, saving money and time for Healthcare providers and bringing peace of mind to staff.

LEGAL


Health and Safety law is also criminal law. Hospitals and Healthcare establishments are subject to prosecution if they do not adhere to current or forthcoming guidelines relating to the prevention of sharps injuries.

Financial considerations are not an excuse for Member States failing to fully implement the Directive, and there are legal precedents (e.g. in Scotland in 2004) that state that cost alone cannot be used as a reason for not adopting safety engineered devices or for changing work practices to comply with European health and safety Directives.

In 2010 a Healthcare Worker contracted hepatitis C after sustaining a needlestick injury: The hospital trust was fined more than £20,000.¹⁰

Worcestershire Acute Hospitals NHS Trust NHS trust was fined £12,500 and ordered to pay £9,000 costs after pleading guilty to breaching the Health and Safety at Work Act, and the control of substances hazardous to health regulations.¹¹

Adopting of the Magellan™ safety needle will keep your hospital or healthcare service within the law, potentially saving expensive and damaging litigation costs, time, and your reputational standards.



*“What happens
if we ignore
the new law?”*

Guidance

The Covidien Safety Day Initiative

Needlestick injuries and their effects continue to be major concerns for those involved in the healthcare system, understandably so when considered alongside the fact that there are 23 known blood-borne pathogens, including hepatitis B, C and HIV, which can be spread through contaminated needlesticks.¹²

'The Covidien Safety Day' campaign¹ on World Aids Day, Dec 1st 2012, where over 65 hospitals from 7 European countries participated in an initiative to highlight the danger of blood-borne injuries, and the potential damage they can cause to the Healthcare Workers (HCW) exposed. The 204 HCW participants - incorporating A+E, ICU and ward based staff - were given training on the product, so they could use it during the World Aids Day before being asked to complete a questionnaire looking at specific product features and wider issues surrounding needlestick injuries. Their responses highlighted the Magellan™ safety needle's valuable safety feature, ease of use and performance effectiveness.



Key Facts

In Europe, 94% of Healthcare Workers interviewed by Covidien said they knew a colleague that had experienced a needlestick injury, and 59% said that they had experienced one themselves.¹

- Although the risk of infection following a needlestick injury from an HIV infection source is low (0.3%) it has significant impact.¹³
- The risk of infection from Hepatitis B can be as high as 30%.¹⁴
- Once caught, Hepatitis C will remain with the patient for the rest of their life.¹⁵


References

- 1 European Findings Summary, The Covidien Safety Day Campaign, 2013.
- 2 Estimate comes from the European Agency for Health and Safety at Work
- 3 Jagger J, Bentley M, Juillet E. Direct Cost of Follow-up for Percutaneous and Mucocutaneous Exposures to At-Risk Body Fluids: Data from two hospitals, Advances In Exposure Prevention - A Publication for the Prevention of Occupational Transmission of Blood-borne Pathogens p, 1. Vol 3, No. 3 1998.
- 4 'Needlestick Injuries: Incidence and Cost in the United States, United Kingdom, Germany, France, Italy and Spain.' Biomedicine International (2010) 1: 41-49 (accessed 7th February 2013) <http://www.bmjjournal.org/index.php/bmi/article/view/20/14>.
- 5 A. Wittman, C. Thümer, B. Neukirch, F. Hoffman, N. Kralji, S. Schroeble "Kosten einer Kanülenstichverletzung" 09-2004.
- 6 Il Costo Delle Ferite Accidentali Da Aghi E 'Impatto Dei Dispositivi di Sicurezza Per La Prevenzioe Dal Rischio Di Puntura Incidentale. Mecosan – Management ed economia Sanitaria – n. 58 – 2006.
- 7 Bevan Brittan LLP are your sharps policies and procedures up to scratch? February 2011
- 8 NHS Dumfries Galloway London June 2012 Sharp Injury Case Study.pdf
- 9 European Biosafety Network Toolkit for implementation of European Directive on Prevention of Sharps Injuries
- 10 http://www.rcn.org.uk/_data/assets/pdf_file/0008/418490/004135.pdf Sharps Safety. Royal College Of Nursing. (Accessed 11th February 2013).
- 11 http://www.worcesterinfectioncontrol.nhs.uk/index.php?option=com_content&view=article&id=59&Itemid=75
- 12 Wasson D, Sherry D. Needlestick Prevention: Safe practices for healthcare providers and individuals with diabetes mellitus, Infection Control Resource – Prevention Strategies for IC Practitioners and professional nurses, Vol1, No. 3. p. 2.
- 13 <http://www.aidsmap.com/Risk-of-infection/page/1324549/AidsMap, Resources and Testing> (Accessed February 11th 2013).
- 14/15 http://www.ccohs.ca/oshanswers/diseases/needlestick_injuries.html Canadian Centre for Occupational Health And Safety (Accessed 11th February 2013).

The Safety Solution

CONCLUSION

The Covidien Safety Day results reveal the Healthcare Workers' preference for a safety needle that combines reliable usability, excellent everyday performance and effective safety functionality. Moreover, significant concern from Healthcare Workers over the incidence of needlestick injuries and the consequences thereof, the Magellan™ safety needle can provide a cost effective and valuable solution.



Magellan™ Safety Technology

Designed with integral safety shield that secures and permanently locks over the needle after use.

OTHER SAFETY PRODUCTS FROM COVIDIEN

Magellan™ Hypodermic Safety Syringe



Hypodermic Safety Syringe

Magellan™ Insulin Safety Syringe



Insulin Safety Syringe

Magellan™ Tuberculin Safety Syringe



Tuberculin Safety Syringe

Monoject™ SmarTip™ Needleless Cannula



Needleless Med-Prep Cannula

Monoject™ Blunt Fill



Blunt Tip Safety I.V. Access Cannula with Vial Access Pin

ORDERING INFORMATION

Code	Description	Size	Carton	Case
Magellan™ safety Hypodermic needle only				
8881850810	18g x 1"	1.27mm x 2.5cm	50	500
8881850815	18g x 1-1/2"	1.27mm x 3.8cm	50	500
8881850910	19g x 1"	1.067mm x 2.5cm	50	500
8881850915	19g x 1-1/2"	1.067mm x 3.8cm	50	500
8881850010	20g x 1"	0.902m x 2.5cm	50	500
8881850015	20g x 1-1/2"	0.902m x 3.8cm	50	500
8881850158	21g x 5/8"	0.813mm x 1.6cm	50	500
8881850110	21g x 1"	0.813mm x 2.5cm	50	500
8881850115	21g x 1-1/2"	0.813mm x 3.8cm	50	500
8881850210	22g x 1"	0.711mm x 2.5cm	50	500
8881850215	22g x 1-1/2"	0.711mm x 3.8cm	50	500
8881850358	23g x 5/8"	0.635mm x 1.6cm	50	500
8881850310	23g x 1"	0.635mm x 2.5cm	50	500
8881850558	25g x 5/8"	0.508mm x 1.6cm	50	500
8881850510	25g x 1"	0.508mm x 2.5cm	50	500
8881850515	25g x 1-1/2"	0.508mm x 3.8cm	50	500
Magellan™ safety hypodermic needle and syringe pre-attached combinations				
3ml combos				
8881833010	20g x 1"	0.902m x 2.5cm	50	400
8881833015	20g x 1-1/2"	0.902m x 3.8cm	50	400
8881833110	21g x 1"	0.813m x 2.5cm	50	400
8881833210	21g x 1-1/2"	0.813m x 3.8	50	400
8881833115	22g x 1"	0.711m x 2.5cm	50	400
8881833215	22g x 1-1/2"	0.711m x 3.8cm	50	400
8881833310	23g x 1"	0.635m x 2.5cm	50	400
8881833558	25g x 5/8"	0.508m x 1.6cm	50	400
6ml combos				
8881866110	21g x 1"	0.8mm x 25.4mm	50	200
8881866115	21g x 1-1/2"	0.8mm x 38.1mm	50	200
12ml combos				
8881822015	20g x 1-1/2"	0.9mm x 38.1mm	50	200
8881822110	21g x 1"	0.8mm x 25.4mm	50	200
8881822115	21g x 1-1/2"	0.8mm 38.1mm	50	200
8881822215	22g x 1-1/2"	0.7mm x 38.1mm	50	200
Magellan™ Insulin safety needle and syringe				
8881892910	1ml - 29g x 1/2"	0.33mm x 1.3cm	50	500
8881892950	0.5ml - 29g x 1/2"	0.33mm x 1.3cm	50	500
8881892930	0.3ml - 29g x 1/2"	0.33mm x 1.3cm	50	500
8881893010	1ml - 30g x 5/16"	0.305mm x 0.8cm	50	500
8881893050	0.5ml - 30g x 5/16"	0.305mm x 0.8cm	50	500
8881893030	0.3ml - 30g x 5/16"	0.305mm x 0.8cm	50	500
Tuberculin safety needle and syringe				
8881882812	1ml - 28g x 1/2"	0.356mm x 1.3cm	50	500
Blunt needles for drug mixing				
8881202355	19g x 1-1/2"	1.067mm x 3.8cm	25	100
8881305109	18g x 3" Filter aspirator	1.27mm x 7.6cm	25	100
8881305117	18g x 1-1/2" Filter needle	1.27mm x 3.8mm	100	1000
8881305018	20g x 1-1/2" filter needle	0.902mm x 3.8cm	100	1000
Smart Tip				
8881540111	Needless Med prep cannula		100	1000



COVIDIEN, COVIDIEN with logo, the COVIDIEN logo are registered international trademarks of COVIDIEN AG. Magellan is a trademark of a Covidien company. Epinet is a trademark of its respective owner. © 2013 Covidien

MS_SS_2013_EP13_0400

COVIDIEN (UK) COMMERCIAL LTD
4500 PARKWAY,
WHITELEY, FAREHAM,
HAMPSHIRE PO15 7NY
UNITED KINGDOM

+44 (0) 203 027 1757 [T]
+44 (0) 203 027 1758 [F]
uksales@covidien.com [E]

WWW.COVIDIEN.COM